BE851447A - 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique - Google Patents

2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique

Info

Publication number
BE851447A
BE851447A BE174951A BE174951A BE851447A BE 851447 A BE851447 A BE 851447A BE 174951 A BE174951 A BE 174951A BE 174951 A BE174951 A BE 174951A BE 851447 A BE851447 A BE 851447A
Authority
BE
Belgium
Prior art keywords
dimethoxyquinazolines
piperazinyl
pharmacological application
pharmacological
application
Prior art date
Application number
BE174951A
Other languages
English (en)
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of BE851447A publication Critical patent/BE851447A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE174951A 1976-02-18 1977-02-15 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique BE851447A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/659,059 US4060615A (en) 1976-02-18 1976-02-18 2-Piperazinyl-6,7-dimethoxyquinazolines

Publications (1)

Publication Number Publication Date
BE851447A true BE851447A (fr) 1977-08-16

Family

ID=24643862

Family Applications (1)

Application Number Title Priority Date Filing Date
BE174951A BE851447A (fr) 1976-02-18 1977-02-15 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique

Country Status (22)

Country Link
US (1) US4060615A (fr)
JP (1) JPS52100479A (fr)
AU (1) AU505080B2 (fr)
BE (1) BE851447A (fr)
CA (1) CA1090803A (fr)
CH (2) CH620925A5 (fr)
CY (1) CY1155A (fr)
DE (1) DE2707068A1 (fr)
DK (1) DK144010C (fr)
FI (1) FI64586C (fr)
FR (1) FR2341576A1 (fr)
GB (1) GB1545697A (fr)
HK (1) HK32682A (fr)
IE (1) IE44613B1 (fr)
KE (1) KE3221A (fr)
LU (1) LU76779A1 (fr)
MY (1) MY8300172A (fr)
NL (1) NL7701584A (fr)
SE (1) SE431753B (fr)
SG (1) SG30882G (fr)
YU (4) YU42577A (fr)
ZA (1) ZA77587B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
JPS6016948B2 (ja) * 1978-03-29 1985-04-30 住友化学工業株式会社 新規なキナゾリン誘導体及びその製造法
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0022481A1 (fr) * 1979-06-21 1981-01-21 Mitsubishi Yuka Pharmaceutical Co., Ltd. Dérivés de la 5,6-alcoylènepyrimidine, procédés pour leur préparation et préparations pharmaceutiques
GB2068961B (en) * 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
DE3304292A1 (de) * 1982-10-11 1984-04-12 Brown, Boveri & Cie Ag, 6800 Mannheim Verfahren und vorrichtung zum ausregeln von netzfrequenzeinbruechen bei einem gleitdruckbetriebenen dampfkraftwerkblock
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
AT384218B (de) * 1985-12-04 1987-10-12 Gerot Pharmazeutika Verfahren zur herstellung von neuen chinazolin-derivaten
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
CA2077252C (fr) * 1992-08-31 2001-04-10 Khashayar Karimian Methodes de fabrication d'urees et de guanidines et composes intermediaires servant a ces syntheses
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (fr) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
UA46166C2 (uk) * 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
EP1364950A4 (fr) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Derive de pyridopyrimidine ou naphthyridine
CA2449163C (fr) * 2001-05-09 2010-07-13 Bayer Healthcare Ag Utilisation nouvelle d'imidazotriazinones 2-phenyl-substituees
EP1312363A1 (fr) * 2001-09-28 2003-05-21 Pfizer Products Inc. Méthode de traitement et kit comprenant un secrétagogue d'hormone de croissance
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
MXPA04009997A (es) * 2002-04-12 2004-12-13 Celgene Corp Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas.
WO2003086373A1 (fr) * 2002-04-12 2003-10-23 Celgene Corporation Techniques d'identification de modulateurs d'angiogenese, composes decouverts par ces techniques et techniques de traitement utilisant ces composes
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2656566C (fr) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines comme inhibiteurs de la proteine kinase akt
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006039A1 (fr) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothiéno pyrimidines comme inhibiteurs de la protéine kinase akt
NZ573979A (en) * 2006-07-06 2012-02-24 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008151734A1 (fr) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
MX2009014013A (es) * 2007-07-05 2010-01-28 Array Biopharma Inc Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
BRPI0813999A2 (pt) 2007-07-05 2019-10-01 Array Biopharma Inc ciclopentanos de pirimidil como inibidores de akt proteína cinase
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
NZ586720A (en) * 2008-01-09 2012-11-30 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
EP2247578B1 (fr) * 2008-01-09 2013-05-22 Array Biopharma, Inc. Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
WO2009120296A1 (fr) * 2008-03-24 2009-10-01 Celgene Corporation Traitement du psoriasis ou du rhumatisme psoriasique par le cyclopropyl-n-{2-{(1s)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-3-oxoisoindoline-4-yl}carboxamide
SG194045A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
KR20140022053A (ko) 2011-04-01 2014-02-21 제넨테크, 인크. Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
US11944624B2 (en) * 2017-07-06 2024-04-02 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
JPS536156B2 (fr) * 1972-10-30 1978-03-04
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives

Also Published As

Publication number Publication date
FI770486A (fr) 1977-08-19
CH620925A5 (fr) 1980-12-31
IE44613B1 (en) 1982-01-27
IE44613L (en) 1977-08-18
FI64586B (fi) 1983-08-31
ZA77587B (en) 1977-12-28
CY1155A (en) 1983-01-28
CA1090803A (fr) 1980-12-02
YU42577A (en) 1982-10-31
FR2341576A1 (fr) 1977-09-16
MY8300172A (en) 1983-12-31
JPS52100479A (en) 1977-08-23
AU505080B2 (en) 1979-11-08
FR2341576B1 (fr) 1979-01-19
US4060615A (en) 1977-11-29
SG30882G (en) 1983-07-08
YU165282A (en) 1982-10-31
SE431753B (sv) 1984-02-27
YU40622B (en) 1986-02-28
HK32682A (en) 1982-07-23
LU76779A1 (fr) 1977-08-19
CH623051A5 (fr) 1981-05-15
YU165382A (en) 1982-10-31
DK144010C (da) 1982-04-26
AU2189777A (en) 1978-08-10
GB1545697A (en) 1979-05-10
FI64586C (fi) 1983-12-12
SE7701731L (sv) 1977-08-19
DK65077A (da) 1977-08-19
YU165482A (en) 1982-10-31
DE2707068A1 (de) 1977-09-01
NL7701584A (nl) 1977-08-22
KE3221A (en) 1982-08-13
DK144010B (da) 1981-11-16

Similar Documents

Publication Publication Date Title
BE851447A (fr) 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique
BE859012A (fr) Derives de 4-n-acylfortimicines b, leur preparation et leur application
NL7713141A (nl) Scheidingssamenstel.
FI781386A (fi) Farmakologiskt aktiva komponenter
SE7608748L (sv) Acyl-sackariner och acyl-3-oxo-1,2-bensisotiazoliner
FR2343870A2 (fr) Structure de mur-rideau
FI781490A (fi) Farmakologiskt aktiva komponenter
FI772829A (fi) Farmakologiskt aktiva foereningar
BE860736A (fr) Derives de piperidine et leur preparation.
BE847396A (fr) Alkoxysilanes et leur preparation,
BE871702A (fr) Isochromanes, isothiochromanes, 2-benzoxepines et 2-benzothiepines
BE855471A (fr) Nonapeptides nouveaux et leur preparation
BE853027A (fr) Nouvelles n-oxy-amidino-urees
BE871807A (fr) 4-quinolyl-guanidines, leur preparation et leur utilisation
BE859987A (fr) Nouvelles aza-8 purinones-6
DK259777A (da) Paraply
FR2342290A1 (fr) Aminoalkylpyrrolobenzoxo-aza-alcanes, leur preparation et leurs applications
FR2545826B1 (fr) Dihydropyridylimidates cycliques, et leur application pharmacologique
BE859221A (fr) Bis-carbamoylsulfures n-substitues et leur preparation
BE869352A (fr) Nouvelles nitrosourees et leur application
BE853203A (fr) Antibiotiques anti-tumerus ma 144-m1 et ma 144-m2
BE858682A (fr) Nouvelles 11-deoxy-11-oxaprostaglandines
DK408577A (da) Indgivelsessaet
BE861694A (fr) 3-carboxy-4-oxo-1,4-dihydro-1,8-naphtyridines et leur preparation
NL7808443A (nl) Arylfosfonieten en arylthiofosfonieten.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: BRISTOL-MYERS CY

Effective date: 19850215